Abstract 117P
Background
PARP inhibitors are now the standard of care for patients with ovarian cancer. The determination of HRD status has become essential to predict sensitivity to these targeted therapies, and has to be integrated in routine oncology assays, beyond the search for BRCA1/2 pathogenic variants. We present the integration of an HRD assay based on tumor shallow whole genome sequencing (sWGS) fully integrated in an existing NGS workflow dedicated to somatic oncology.
Methods
25 samples from ovarian cancer with HRD status was determined using two CE-IVD assays (5 Sofia Genetics / 20 Myriad Genetics). Samples have been re-analysed, starting from FFPE blocks. We performed new DNA extractions from FFPE blocks followed by our dedicated workflow for solid tumor using NGS sequencing. DNA samples were prepared using hybridation method (Twist BioScience®) with Unique Molecular Identifiers (UMI). Part of libraries from HRD samples were collected before the capture step, and directly pooled for sequencing on Illumina® NextSeq 500. sWGS produced were analysed by a dedicated CE-IVD Bioinformatic pipeline for HRD status determination (SeqOne®).
Results
3 different runs of 10 samples each have been sequenced for replicability evaluation. No failure were encountered on any of the sequenced samples. The mean depth, Q30 quality and duplicate rates for sWGS produced were respectively 1.12X / 88.8% / 1.94%, far above the minimum requirements for analysis (> 0.1X). Replicability analysis show an average variation of 4% of the final HRD score. Regarding the HRD status determination, our results show an agreement of 93.3% with the status previously determined, in line with the results obtained by SeqOne during the validation of their bioinformatic analysis (93%).
Conclusions
Theses results demonstrate innovative integration into routine genetics’s laboratory. This implemented methodology allows us to provide a full report with both BRCA1/BRCA2 variant identification and the HRD status for each patient, in an efficient and cost-effective workflow.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
169P - A real-world molecular pre-screening program in advanced breast cancer (ABC) at Institut Català d'Oncologia l'Hospitalet: Clinical practice study to assess treatment-decision choice based on molecular results
Presenter: David Lluís Garulo
Session: Cocktail & Poster Display session
Resources:
Abstract
170P - KRAS status in patients with pancreatic ductal adenocarcinoma: A single-center study from 2020 to 2023
Presenter: Manukyan Mariam
Session: Cocktail & Poster Display session
Resources:
Abstract
171P - Benefit of next-generation sequencing for lung cancer patients in a limited-resource area
Presenter: Kijjakom Thanasombunsukh
Session: Cocktail & Poster Display session
Resources:
Abstract
172P - Survival prediction using CT based radiomic features in patients of pancreatic cancer treated by chemotherapy followed by SBRT: A pilot study
Presenter: Divya Khosla
Session: Cocktail & Poster Display session
Resources:
Abstract
173P - Overcoming monocyte imbalance and T cell exhaustion in obesity-associated colorectal cancer liver metastasis
Presenter: Alyssa Cristea
Session: Cocktail & Poster Display session
Resources:
Abstract
174TiP - A pivotal clinical trial of a functional ex vivo organ culture assay for cancer precision medicine
Presenter: Sandra Hanks
Session: Cocktail & Poster Display session
Resources:
Abstract
177TiP - Myeloid-derived suppressor cells in the peripheral blood of patients with colorectal cancer: A trial in progress
Presenter: Hans Raskov
Session: Cocktail & Poster Display session
Resources:
Abstract